Skip to main content
. Author manuscript; available in PMC: 2010 Sep 8.
Published in final edited form as: Mol Cancer Res. 2009 Sep 8;7(9):1487–1496. doi: 10.1158/1541-7786.MCR-09-0166

FIGURE 4.

FIGURE 4

ABT-737 in combination with cisplatin induces apoptosis. A. MTT assay of iMPEC-7_pcDNA3 (top) and iMPEC-7_Bcl-2 (bottom). iMPEC-7_pcDNA3 and iMPEC-7_Bcl-2 showed sensitivity to the ABT-737/cisplatin combination. iMPEC-7_pcDNA3 was killed with lower concentrations of ABT-737/cisplatin than iMPEC-7_Bcl-2 (arrows). Viabilities are relative to time 0. B. Indirect immunofluorescence for cytochrome c release. Arrows, cells with released cytochrome c at 3 d. Percentage of cytochrome c release (bottom left corner of each image). Bar, 10 μm. C. iMPEC-7_Bcl-2 showed high levels of active caspase-3 in response to 10 μmol/L of ABT-737 and 12.5 μm of cisplatin (top, red box). Western blot showing Mcl-1 levels with 12.5 μmol/L of cisplatin in iMPEC_pcDNA3 and iMPEC_Bcl-2 cells (bottom). D. Quantitation of activated caspase-3. Bars, SD based on three independent experiments.